Krystal Biotech buy Guggenheim
Start price
27.02.24
/
50%
€152.00
Target price
27.02.25
€161.18
Performance (%)
14.14%
End price
28.02.25
€173.50
Summary
This prediction ended on 28.02.25 with a price of €173.50. The BUY prediction by Guggenheim finished with a performance of 14.14%. Guggenheim has a follow-up prediction for Krystal Biotech where he still thinks Krystal Biotech is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Krystal Biotech | 0.969% | 0.969% | -31.832% |
| iShares Core DAX® | 1.097% | 4.456% | 31.213% |
| iShares Nasdaq 100 | -0.089% | 4.218% | 8.410% |
| iShares Nikkei 225® | 5.046% | 5.461% | 2.669% |
| iShares S&P 500 | 0.416% | 3.910% | 6.692% |
Comments by Guggenheim for this prediction
In the thread Krystal Biotech diskutieren
Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $130.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
In the thread Trading Krystal Biotech
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten